SCHEMBL7042468

SCHEMBL7042468

COc1nn(-c2ccc(NC(=O)c3ccc(C(F)(F)F)cc3)c(F)c2)c(=O)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPL P06858 1/20 0.60
LIPC P11150 1/20 0.60
LIPE Q05469 1/20 0.60
ABHD16A O95870 1/20 0.49
ABCG2 Q9UNQ0 9/20 0.48
MGLL Q99685 4/20 0.47
FAAH O00519 2/20 0.47
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ABCB1 P08183 1/20 0.44
KDM4E B2RXH2 3/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SCN9A Q15858 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7046269 0.92 LPL (0.71) LPLLIPCLIPEABHD16AABCG2
SCHEMBL7040752 0.82 MGLL (0.57) LPLLIPCLIPEABCG2MGLL
SCHEMBL6604889 0.79 LPL (0.72) LPLLIPCLIPEABHD16AABCG2
SCHEMBL6602316 0.78 LPL (0.64) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7047919 0.75 LPL (1.00) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7043147 0.75 MGLL (0.81) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7047574 0.73 FAAH (0.49) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7046042 0.72 MGLL (0.72) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7571649 0.72 MGLL (0.72) LPLLIPCLIPEABHD16AMGLL
SCHEMBL7045989 0.72 MGLL (0.66) LPLLIPCLIPEABHD16AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase AVENTIS PHARMA DEUTSCHLAND GMBH 2003-12-25 US disclosed
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 LPL 1845/4885LIPC 554/4885LIPE 1909/4885
US-20030236288-A1 Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase PNLIP, CEL, LIPE LPL 4/4885LIPC 7/4885LIPE 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.